Rebecca M. Lombel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca M. Lombel has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Debbie S. Gipson
Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
2 shared publications Elisabeth M. Hodson
The Children’s Hospital at Westmead
2 shared publications- Bryan S. Sack
Department of Urology University of Michigan Ann Arbor Michigan USA
1 shared publication - Lavjay Butani
Division of Pediatric Nephrology, Department of Pediatrics, University of California, Sacramento, USA
1 shared publication Paul R. Brakeman
Division of Pediatric Nephrology, University of California, San Francisco, San Francisco, CA
1 shared publication
Latest Publications
- Open Access
- 6 September 2022
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 29 (3) , 308-317
Urologic Considerations in Pediatric Chronic Kidney Disease
- 6 September 2022
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 29 (3) , 308-317
Open AccessUrologic Considerations in Pediatric Chronic Kidney Disease
- 5 October 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (3) , 409-414
Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO
Kidney Disease: Improving Global Outcomes (KDIGO) recently published the clinical practice guideline on glomerulonephritis (GN) to assist the practitioner caring for patients with GN. Chapter 4 of the guideline focuses on managing children aged 1–18 years with steroid-resistant nephrotic syndrome (SRNS), defined by an inability to achieve complete remission with corticosteroid therapy. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides both the guideline recommendations and a brief review of relevant treatment trials related to each recommendation. This précis serves as a summary of the complete guidelines recently published.
- 5 October 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (3) , 409-414
Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO
Kidney Disease: Improving Global Outcomes (KDIGO) recently published the clinical practice guideline on glomerulonephritis (GN) to assist the practitioner caring for patients with GN. Chapter 4 of the guideline focuses on managing children aged 1–18 years with steroid-resistant nephrotic syndrome (SRNS), defined by an inability to achieve complete remission with corticosteroid therapy. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides both the guideline recommendations and a brief review of relevant treatment trials related to each recommendation. This précis serves as a summary of the complete guidelines recently published.
- Top Cited Papers
- 3 October 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (3) , 415-426
Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on glomerulonephritis (GN) is intended to assist the practitioner caring for patients with GN. Two chapters of this guideline focus specifically on nephrotic syndrome in children. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Critical appraisal of the quality of evidence and strength of recommendations followed the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach. Chapters 3 and 4 of the guideline focus on the management of nephrotic syndrome in children aged 1–18 years. Guideline recommendations for children who have steroid-sensitive nephrotic syndrome (SNSS), defined by their response to corticosteroid therapy with complete remission, are addressed here. Recommendations for those with steroid-resistant nephrotic syndrome (SRNS) (i.e., do not achieve complete remission) are discussed in the companion article. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides a short description of the KDIGO process, the guideline recommendations for treatment of SSNS in children and a brief review of relevant treatment trials related to each recommendation.
- 3 October 2012
- Published by Springer Nature in Pediatric Nephrology
- Vol. 28 (3) , 415-426
Top Cited PapersTreatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on glomerulonephritis (GN) is intended to assist the practitioner caring for patients with GN. Two chapters of this guideline focus specifically on nephrotic syndrome in children. Guideline development followed a thorough evidence review, and management recommendations and suggestions were based on the best available evidence. Critical appraisal of the quality of evidence and strength of recommendations followed the Grades of Recommendation Assessment, Development and Evaluation (GRADE) approach. Chapters 3 and 4 of the guideline focus on the management of nephrotic syndrome in children aged 1–18 years. Guideline recommendations for children who have steroid-sensitive nephrotic syndrome (SNSS), defined by their response to corticosteroid therapy with complete remission, are addressed here. Recommendations for those with steroid-resistant nephrotic syndrome (SRNS) (i.e., do not achieve complete remission) are discussed in the companion article. Limitations of the evidence, including the paucity of large-scale randomized controlled trials, are discussed. This article provides a short description of the KDIGO process, the guideline recommendations for treatment of SSNS in children and a brief review of relevant treatment trials related to each recommendation.